

# 2018

## Research workbook

*France*

---

## **2018 National report (2017 data) to the EMCDDA by the French Reitox National Focal Point**

**Supervision:** Julien Morel d'Arleux

**Coordination and editorial:** Aurélie Lermenier-Jeannet et Anne de l'Eprevier

### **Contribution to the workbooks**

- 1.1 *Drug Policy*: Cristina Díaz-Gómez, Julie-Émilie Adès
- 1.2 *Legal Framework*: Caroline Protais, Cristina Díaz-Gómez
- 2 *Drugs*: Olivier Le Nézet, Thomas Néfau, Michel Gandilhon, Agnès Cadet-Taïrou, Eric Janssen, Julie-Émilie Adès
- 3.1 *Prevention*: Carine Mutatayi
- 3.2 *Treatment*: Christophe Palle, Anne-Claire Brisacier
- 3.3 *Best Practice*: Carine Mutatayi
- 3.4 *Harms and Harm Reduction*: Anne-Claire Brisacier, Cristina Díaz-Gómez, Thomas Néfau, Agnès Cadet-Taïrou
- 4 *Drug Market and Crime*: Michel Gandilhon, Thomas Néfau, Caroline Protais
- 5.1 *Prison*: Caroline Protais, Anne-Claire Brisacier
- 5.2 *Research*: Isabelle Michot, Maitena Milhet

**Proofreading (French version):** Julie-Émilie Adès, Julien Morel d'Arleux, Ivana Obradovic (OFDT) ; Nicolas Prisse, president of the Interministerial Mission for Combating Drugs and Addictive Behaviours, and the project managers of the MILDECA

**Proofreading (English version):** Anne de l'Eprevier

**Bibliographic references:** Isabelle Michot

**Legal references:** Anne de l'Eprevier

## **Table of Contents**

<b>T0. Summary .....</b>	4
<b>T1.1 Drug-related research .....</b>	6
<b>T2. Trends. Not applicable for this workbook.....</b>	9
<b>T3. New developments .....</b>	9
<b>T4. Additional information.....</b>	19
<b>T5. Notes and queries .....</b>	19
<b>T6. Sources and methodology.....</b>	20

The EMCDDA is investigating how the submission of the workbooks could be made easier through the use of technology. In the first instance, a pilot using templates in Word with defined fields to distinguish the answers to questions is being tried. The outcome of the pilot should be to evaluate the usefulness of this tool and establish the parameters of any future IT project.

We are using the pre-filled templates in the first instance as part of the pilot.

1. The principle is that a template is produced for each workbook, and one version of this is provided to each country, in some instances pre-filled.
2. Answers to the questions should be entered into the “fields” in the template. The fields have been named with the question number (e.g. T.2.1). It will be possible to extract the contents of the fields using the field names.
3. Fields are usually displayed within a border, and indicated by “Click here to enter text”. Fields have been set up so that they cannot be deleted (their contents can be deleted). They grow in size automatically.
4. The completed template/workbook represents the working document between the NFP and the EMCDDA. Comments can be used to enhance the dialogue between the EMCDDA and the NFP. Track changes are implemented to develop a commonly understood text and to avoid duplication of work.

When responding to the workbook, please be certain to use the fields associated with each question, to allow the EMCDDA to identify the relevant parts.

## T0. Summary

Please provide an abstract of this workbook (target: 500 words) under the following headings:

- National profile  
In this section please summarise the most relevant information included in the following sections, namely:
  - main research institutions involved in the research on drugs and relevant funding institutions;
  - sources for the research at the national level;
  - the role of drug-related research in the context of your national drug strategy,
  - if applicable, the role of your national drug observatory in the implementation, execution or coordination of drug-related research activities in the country;
  - national or regional scientific journals publishing drug related research and main drug-related research projects, ongoing or planned in the country (national and/or international)
- New development

### National profile

In France, the Ministry of National Education, Higher Education and Research (MENESR) designs, coordinates and implements national policy on research and innovation. Two primary academic organisations, the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM), cover a wide range of research areas, from neurosciences, through public health and clinical research to social sciences.

The French National Focal Point (OFDT) is the main body involved in drug-related data collection, studies and network development. It collaborates extensively with national and European drug-related research teams. Dissemination of data and research results are also part of its mandate, together with publishing in national and international scientific journals, and promoting the use of research results in practice and policymaking.

The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA) is the central structure responsible to the Prime Minister for coordinating governmental action in the drugs field. Part of its role is to promote and fund drug-related research.

The list of research projects in France has been carried out within the framework of the ERANID project for the years 2010-2013 but has not been renewed since.

This workbook therefore lists the bibliographical references illustrating the productivity of French researchers in the field of addictions for 2017 and the first quarter of 2018.

**New development** (including a description of research priorities, if available)

The national priorities in terms of research in the field of addiction are defined in the MILDECA governmental plan. The new national action plan on addiction, adopted over the period 2018-2022, defines five priority lines of research covering 1) drug use, 2) prevention, 3) harm reduction measures and treatment, 4) penal measures, together with 5) supply reduction.

- 1) As regards drug use, the plan promotes a general increase in knowledge, along with analysis of impact arising from environmental factors and health care delivery based on individual pathways.
- 2) In terms of prevention, the plan highlights the importance of having greater insight into prevention measures and the evaluation of the quality of prevention interventions in the school and occupational setting.
- 3) In terms of harm reduction measures and treatment, the main objective of this research is to document more clearly the cost-effectiveness of the policies and interventions. The authorities also draw attention to the importance of shedding light on the consequences of use on health (mental health, infectious diseases, morbidity related to misuse, other somatic consequences and death).
- 4) The authorities also wish to promote an impact assessment culture with regard to legal measures, based on the methods introduced in English-speaking countries.
- 5) As regards research relating to drug supply, the plan notably encourages improved monitoring of new psychoactive substances and studies on the changes in supply.

This new national strategy on addiction was adopted in December 2018 (see Policy workbook for more details).

## T1.1 Drug-related research<sup>1</sup>

The purpose of this section is to

- Describe the organization of drug-related research in your country
- Provide a summary of specific resources on drug-related research available in your country
- Update the available information already provided to the EMCDDA (workbook will be pre-filled).

Please structure your answers around the following questions.

T1.1.1 Please update the main drug-related research institutions/associations/bodies (public or private) in your country.

Please provide links, also to pages in English, if available.

- Centre National de la Recherche Scientifique (CNRS):  
<http://www.cnrs.fr/index.html>
- Conservatoire National des Arts et Métiers (CNAM):  
<http://the.cnam.eu/>
- École des Hautes Études en Santé Publique (EHESP):  
<http://www.ehesp.fr/en/>
- École des Hautes Études en Sciences Sociales (EHESS):  
<https://www.ehess.fr/en>
- Fédération Nationale des Observatoires Régionaux de la Santé (FNORS):  
<http://www.fnors.org/index.html>
- Fondation Nationale des Sciences Politiques (FNSP):  
<http://www.sciencespo.fr/en/home>
- Institut de Recherche en Santé Publique (GIS-IReSP):  
<http://www.iresp.net/>
- Institut de Recherche pour le Développement (IRD):  
<http://en.ird.fr/ird.fr>
- Institut National de la Recherche Agronomique (INRA):  
<http://www.inra.fr/en>
- Institut National de la Santé et de la Recherche Médicale (INSERM):  
<http://english.inserm.fr/>
- Observatoire Français des Drogues et des Toxicomanies (OFDT):  
<https://en.ofdt.fr/>
- Santé publique France (SpF)  
<http://www.santepubliquefrance.fr/Infos/About-Sante-publique-France>

<sup>1</sup> "Drug-related research involves performing a study on illicit drugs, which may involve a range of disciplines, through the use of scientifically accepted methods and procedures, in order to test a hypothesis or answer a specific question." (EMCDDA, 2012 [Drug-related research in Europe: recent developments and future perspectives](#))

T1.1.2 Please update the main institutions/associations/bodies/programmes (public or private) funding drug-related research in your country.

Please provide links, also to pages in English, if available.

- The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA: <http://www.droques.gouv.fr/page-simple/mildeca-interministerial-mission-combating-drugs-and-addictive-behaviours>) is the central structure responsible to the Prime Minister for coordinating governmental action in the drugs field. Part of his role is to promote and fund drug related research. In line with the last Plan 2013–17, the MILDECA supported new annual calls for proposals and extended collaborations with research organizations/universities and with the ANR. It also promoted clinical research networks and dissemination initiatives towards the scientific community and policy makers. The Ministry of Research together with the MILDECA also supported the ERANID research network gathering major academic research centres (INSERM, CNRS) and agencies including the national focal point itself.
- The Ministry of National Education, Higher Education and Research (MENESR: <http://www.education.gouv.fr/>) designs, coordinates and implements national policy on research and innovation. A large scope of research areas ranging from neurosciences, through public health and clinical research to social sciences is mainly covered by two major academic operators: the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM).
- The French Research Agency (*Agence Nationale de la Recherche* – ANR: <http://www.agence-nationale-recherche.fr/en/project-based-funding-to-advance-french-research/>) is in charge of programming national research and innovation. The agency establishes the thematic priorities of research and allocates the resources. Every year, the agency launches calls for tenders covering a large spectrum of scientific areas.
- The Ministry of Health (<http://www.sante.gouv.fr/>) funds, in specific years, clinical projects on addiction treatment in hospitals (under the programme “*Programme Hospitalier de Recherche Clinique*” - PHRC). It also funds studies on specific populations of drug users, interventions (prevention, treatment, harm reduction) or legal disposition.
- The National Research Agency on AIDS (*Agence Nationale de Recherche sur le Sida* – ANRS: <http://www.anrs.fr/>) and the French Public Health Agency (*Santé publique France*: <http://www.santepubliquefrance.fr/Infos/About-Sante-publique-France>) implement regular surveys and research projects on the links between injecting drug use and infectious diseases (mainly HIV and HCV).
- The French National Cancer Institute (*Institut national du cancer* – INCa: <http://en.e-cancer.fr/>) is the preeminent health and science agency in charge of cancer control in France, created in 2004. It reports to the ministries for Health and for Research. About half of its budget (€100 million) is allocated to research funding. Each year, the Institute organises more than fifteen competitive calls for proposals in the areas of research, public health, cancer care organisation and patient information.

NGOs and foundations (such as the *Fondation de France*) representing practitioners, users and companies (alcohol suppliers, tobacco industry and pharmaceutical laboratories) also regularly fund surveys and research project in these areas.

T1.1.3 Please update the list of the main national scientific journals where drug-related research is published in your country.  
 Please provide links, also to pages in English, if available.

Name	Topic	Language	Abstract
Addiction(s) : recherches et pratiques <a href="https://www.federationaddiction.fr/productions/revue/">https://www.federationaddiction.fr/productions/revue/</a>	Treatment	French	French
Alcoologie et Addictologie <a href="http://www.alcoologie-et-addictologie.fr/">http://www.alcoologie-et-addictologie.fr/</a> <a href="http://www.alcoologie-et-addictologie.fr/index.php/aa">http://www.alcoologie-et-addictologie.fr/index.php/aa</a>	Treatment	French, English	English
Archives des Maladies Professionnelles et de l'Environnement <a href="https://www.sciencedirect.com/science/journal/17758785">https://www.sciencedirect.com/science/journal/17758785</a>	Treatment	French	English
Bulletin Épidémiologique Hebdomadaire <a href="http://invs.santepubliquefrance.fr//Publications-et-outils/BEH-Bulletin-epidemiologique-hebdomadaire">http://invs.santepubliquefrance.fr//Publications-et-outils/BEH-Bulletin-epidemiologique-hebdomadaire</a>	Epidemiology and public health	French	English
Le Courier des Addictions <a href="http://www.edimark.fr/courrier-addictions">http://www.edimark.fr/courrier-addictions</a>	Addiction all topics	French	English
Déviance et Société <a href="https://www.cairn.info/revue-deviance-et-societe.htm">https://www.cairn.info/revue-deviance-et-societe.htm</a> <a href="https://www.cairn-int.info/journal-deviance-et-societe.htm">https://www.cairn-int.info/journal-deviance-et-societe.htm</a>	Sociology and political science	French	English
L'Encéphale <a href="https://www.sciencedirect.com/science/journal/00137006">https://www.sciencedirect.com/science/journal/00137006</a>	Treatment	French	English
Médecine/sciences <a href="https://www.medecinesciences.org/">https://www.medecinesciences.org/</a> <a href="https://www.medecinesciences.org/en/">https://www.medecinesciences.org/en/</a>	Health	French	English
Politix, revue des sciences sociales du politique <a href="https://www.cairn.info/revue-politix.htm">https://www.cairn.info/revue-politix.htm</a> <a href="https://www.cairn-int.info/journal-politix.htm">https://www.cairn-int.info/journal-politix.htm</a>	Human and social sciences	French	English
La Presse Médicale <a href="https://www.sciencedirect.com/science/journal/07554982">https://www.sciencedirect.com/science/journal/07554982</a>	Health	French	English
Psychotropes, Revue internationale des toxicomanies et des addictions <a href="https://www.cairn.info/revue-psychotropes.htm">https://www.cairn.info/revue-psychotropes.htm</a>	Treatment	French	English
Revue d'Épidémiologie et de Santé Publique <a href="https://www.sciencedirect.com/journal/revue-deepidemiologie-et-de-sante-publique">https://www.sciencedirect.com/journal/revue-deepidemiologie-et-de-sante-publique</a>	Epidemiology and public health	French, English	English
Revue Française des Affaires Sociales <a href="https://www.cairn.info/revue-francaise-des-affaires-sociales.htm">https://www.cairn.info/revue-francaise-des-affaires-sociales.htm</a> <a href="https://www.cairn-int.info/journal-revue-francaise-des-affaires-sociales.htm">https://www.cairn-int.info/journal-revue-francaise-des-affaires-sociales.htm</a>	Human and social sciences	French	English
Revue Française de Sociologie <a href="https://www.cairn-int.info/revue.php?ID_REVUE=E_RFS">https://www.cairn-int.info/revue.php?ID_REVUE=E_RFS</a>	Sociology	English, French	English

<a href="https://www.cairn-int.info/journal-revue-francaise-de-sociologie.htm">https://www.cairn-int.info/journal-revue-francaise-de-sociologie.htm</a>			
Santé Publique <a href="https://www.cairn.info/revue-sante-publique.htm">https://www.cairn.info/revue-sante-publique.htm</a> <a href="https://www.cairn-int.info/journal-sante-publique.htm">https://www.cairn-int.info/journal-sante-publique.htm</a>	Epidemiology and public health	French	English
Sciences Sociales et Santé <a href="http://www.jle.com/fr/revues/ssss/revue.phtml">http://www.jle.com/fr/revues/ssss/revue.phtml</a> <a href="http://www.jle.com/en/revues/ssss/revue.phtml">http://www.jle.com/en/revues/ssss/revue.phtml</a>	Human and social sciences	French, English	English
Sociétés Contemporaines <a href="http://sciencespo.giantchair.com/revues/societescontemporaines/">http://sciencespo.giantchair.com/revues/societescontemporaines/</a> <a href="http://www.pressesdesciencespo.fr/en/revues/societescontemporaines/">http://www.pressesdesciencespo.fr/en/revues/societescontemporaines/</a>	Sociology	French	English
Sociologie <a href="https://www.cairn.info/revue-sociologie.htm">https://www.cairn.info/revue-sociologie.htm</a> <a href="https://www.cairn-int.info/review.php?ID_REVUE=E_SOCIO">https://www.cairn-int.info/review.php?ID_REVUE=E_SOCIO</a>	Sociology	French	English
Thérapie <a href="https://www.sciencedirect.com/journal/therapie">https://www.sciencedirect.com/journal/therapie</a>	Treatment	French, English	English
Toxicologie Analytique et Clinique <a href="https://www.sciencedirect.com/science/journal/23520078">https://www.sciencedirect.com/science/journal/23520078</a>	Toxicology	French, English	English

T1.1.4 Please update the list of drug-related research relevant websites/resources you would like us to include in your research country profile.

Please provide links, also to pages in English, if available.

In addition to the websites of the main bodies and organisations that conduct and/or finance regularly or occasionally research on addictive behaviour (see T1.1.1 and T1.1.2), two references may be cited: the Research and Safety National Institute for the Prevention of Occupational Accidents and Diseases (INRS: <http://en.inrs.fr/>) and the National Agency for Medicines and Health Products Safety (ANSM: <http://ansm.sante.fr/>).

## T2. Trends.

Not applicable for this workbook.

## T3. New developments

The purpose of this section is to provide information on any notable or topical developments observed in drug-related research in your country **since your last report**.

T1 is used to establish the baseline of the topic in your country. Please focus on any new developments here.

If information on recent notable developments have been included as part of the baseline information for your country, please make reference to that section here. It is not necessary to repeat the information.

T3.1 Please update the list of the main drug-related, recent/on-going (from 2012 on) studies/research projects in your country. Please provide links, also to pages in English, if available.

If possible, classify each study/research project under one of the following categories:

- (1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research);
- (2) Population based and clinical epidemiology (including site surveys, ethnographic studies and acute toxicity studies);
- (3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research);
- (4) Supply, supply reduction and crime;
- (5) Drug policy (including laws, economic issues and strategies);
- (6) Other topics.

If it is not possible to identify the main drug-related on-going studies/research projects in your country, please provide a list of the most relevant current bibliographic references.

## Bibliography 2017-1<sup>st</sup> quarter 2018

### **(1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research)**

Alvarez, J.C., Etting, I., Abe, E., Villa, A. and Fabresse, N. (2017). Identification and quantification of 4-methylcathinone (4-MEC) and 3,4-methylenedioxypyrovalerone (MDPV) in hair by LC-MS/MS after chronic administration. *Forensic Science International* 270 39-45.

Ameline, A., Farrugia, A., Raul, J.S. and Kintz, P. (2017). Retrospective demonstration of 25I-NBOMe acute poisoning using hair analysis. *Current Pharmaceutical Biotechnology* 18 (10) 786-790.

Assemat, G., Dubocq, F., Bayayssac, S., Lamoureux, C., Malet-Martino, M. and Gilard, V. (2017). Screening of "spice" herbal mixtures: From high-field to low-field proton NMR. *Forensic Science International* 279 88-95.

Batisse, A., Marillier, M., Chevallier, C., Bourgogne, E., Grégoire, M., Laprévote, O. et al. (2017). "NRG-3": What's in this? *Toxicologie Analytique et Clinique* 29 (1) 96-100.

Becker, J.A.J., Kieffer, B.L. and Le Merrer, J. (2017). Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol. *Addiction Biology* 22 (5) 1205-1217.

Bellon-Champel, L. and Varescon, I. (2017). Environnement familial et consommation de substances psychoactives à l'adolescence : facteurs de vulnérabilité et d'adaptation [Family and substances use in adolescence: Vulnerability and adaptation factors]. *Annales Médico-Psychologiques* 175 (4) 313-319.

Bottinelli, C., Boucher, A., Airieau, A., Bayard, R. and Bévalot, F. (2017). Intérêt de l'analyse de résidus de toilettes sèches collectés lors d'un festival de musique électronique pour le suivi de consommation de drogues récréatives [Interest of analyzing dry-toilets collected during an electronic music festival to monitor the use of recreational drugs]. *Toxicologie Analytique et Clinique* 29 (2) 212-219.

Busquets-Garcia, A., Soria-Gomez, E., Redon, B., Mackenbach, Y., Vallee, M., Chaouloff, F. et al. (2017). Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. *Molecular Psychiatry* 22 (11) 1594-1603.

- Chappuy, M., Berger-Vergiat, A., Cohen, S., Ragonnet, D. and Boucher, A. (2018). Recherche de stupéfiant par bandelettes urinaires - suspicion de réaction croisée entre fentanyl et fenspiride [Search for narcotics by urine drug testing - suspected cross-reaction between fentanyl and fenspiride]. *Toxicologie Analytique et Clinique* 30 (1) 69-74.
- Contarino, A., Kitchener, P., Vallée, M., Papaleo, F. and Piazza, P.-V. (2017). CRF1 receptor-deficiency increases cocaine reward. *Neuropharmacology* 117 41-48.
- Daveluy, A., Géniaux, H., Baumevieille, M., Létinier, L., Matta, M.-N., Lazès-Charmetant, A. et al. (2018). Parachuting psychoactive substances: Pharmacokinetic clues for harm reduction. *Addictive Behaviors* 78 173-177.
- Dejean, C., Sitko, M., Girardeau, P., Bennabi, A., Caille, S., Cador, M. et al. (2017). Memories of opiate withdrawal emotional states correlate with specific gamma oscillations in the nucleus accumbens. *Neuropsychopharmacology* 42 (5) 1157-1168.
- Delile, J.-M. and Couteron, J.-P. (2017). Cannabis et santé. *Pratiques en santé mentale* 63 (2) 9-14.
- Devault, D.A., Néfau, T., Levi, Y. and Karolak, S. (2017). The removal of illicit drugs and morphine in two waste water treatment plants (WWTPs) under tropical conditions. *Environmental Science and Pollution Research* 24 (33) 25645-25655.
- Djezzar, S. and Batisse, A. (2018). Complications cliniques des nouvelles drogues de synthèse [Clinical complications of new synthetic drugs]. *La Revue du Praticien - Monographie* 68 (1) 79-83.
- Doly, S., Quentin, E., Eddine, R., Tolu, S., Fernandez, S.P., Bertran-Gonzalez, J. et al. (2017). Serotonin 2B receptors in mesoaccumbens dopamine pathway regulate cocaine responses. *Journal of Neuroscience* 37 (43) 10372-10388.
- Dorard, G., Bungener, C., Phan, O., Edel, Y., Corcos, M. and Berthoz, S. (2017). Is alexithymia related to cannabis use disorder? Results from a case-control study in outpatient adolescent cannabis abusers. *Journal of Psychosomatic Research* 95 74-80.
- Dorard, G., Bungener, C., Phan, O., Edel, Y., Corcos, M. and Berthoz, S. (2018). Quelles comorbidités psychiatriques dans la dépendance au cannabis à l'adolescence ? Comparaison de patients consultants et de témoins [Which psychiatric comorbidities in cannabis dependence during adolescence? Comparison of outpatients and controls]. *L'Encéphale* 44 (1) 2-8.
- Dos Santos, M., Salery, M., Forget, B., Garcia Perez, M.A., Betuing, S., Boudier, T. et al. (2017). Rapid synaptogenesis in the nucleus accumbens is induced by a single cocaine administration and stabilized by mitogen-activated protein kinase interacting kinase-1 activity. *Biological Psychiatry* 82 (11) 806-818.
- Fonteneau, M., Filliol, D., Anglard, P., Befort, K., Romieu, P. and Zwiller, J. (2017). Inhibition of DNA methyltransferases regulates cocaine self-administration by rats: a genome-wide DNA methylation study. *Genes, Brain, and Behavior* 16 (3) 313-327.
- Geoffroy, H. and Noble, F. (2017). BDNF during withdrawal. *Vitamins and Hormones* 104 475-496.
- Griner-Abraham, V. (2017). Vieillesse, quand les "accrocs" révèlent les accros [When addiction is revealed in old age]. *Soins Gérontologie* 22 (123) 12-15.
- Hoffmann, H.M., Crouzin, N., Moreno, E., Raivio, N., Fuentes, S., McCormick, P.J. et al. (2017). Long-lasting impairment of mGluR5-activated intracellular pathways in the striatum after withdrawal of cocaine self-administration. *International Journal of Neuropsychopharmacology* 20 (1) 72-82.

- Hubert, C., Roosen, M., Levi, Y. and Karolak, S. (2017). Validation of an ultra-high-performance liquid chromatography-tandem mass spectrometry method to quantify illicit drug and pharmaceutical residues in wastewater using accuracy profile approach. *Journal of Chromatography A* 1500 136-144.
- Istin, M., Thiriet, N. and Solinas, M. (2017). Behavioral flexibility predicts increased ability to resist excessive methamphetamine self-administration. *Addiction Biology* 22 (4) 958-966.
- Julien, J.-P. (2017). Cannabis repetita et santé mentale. *Pratiques en santé mentale* 63 (2) 45-49.
- Karila, L., Lafaye, G., Coscas, S., Blecha, L. and Benyamina, A. (2017). Le cannabis : addiction. Conséquences aiguës et chroniques. *Pratiques en santé mentale* 63 (2) 15-20.
- Karila, L., Lafaye, G., Scocard, A., Cottencin, O. and Benyamina, A. (2017). MDPV and alpha-PVP use in humans: The twisted sisters. *Neuropharmacology* 10.1016/j.neuropharm.2017.10.007.
- Keramati, M., Durand, A., Girardeau, P., Gutkin, B. and Ahmed, S.H. (2017). Cocaine addiction as a homeostatic reinforcement learning disorder. *Psychological Review* 124 (2) 130-153.
- Lafragette, A., Bardo, M.T., Lardeux, V., Solinas, M. and Thiriet, N. (2017). Reduction of cocaine-induced locomotor effects by enriched environment is associated with cell-specific accumulation of DeltaFosB in striatal and cortical subregions. *International Journal of Neuropsychopharmacology* 20 (3) 237-246.
- Lalanne, L., Ayrancı, G., Filliol, D., Gaveriaux-Ruff, C., Befort, K., Kieffer, B.L. et al. (2017). Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence. *Addiction Biology* 22 (4) 1010-1021.
- Lalanne, L., Ferrand-Devouge, E., Kirchherr, S., Rauch, L., Koning, E., Speeg, C. et al. (2017). Impaired contrast sensitivity at low spatial frequency in cannabis users with early onset. *European Neuropsychopharmacology* 27 (12) 1289-1297.
- Lamarche, F., Cottet-Rousselle, C., Barret, L. and Fontaine, E. (2017). Protection of PC12 cells from cocaine-induced cell death by inhibiting mitochondrial permeability transition. *Neurochemistry International* 109 34-40.
- Lamy, S., Hennart, B., Houivet, E., Dulaurent, S., Delavenne, H., Benichou, J. et al. (2017). Assessment of tobacco, alcohol and cannabinoid metabolites in 645 meconium samples of newborns compared to maternal self-reports. *Journal of Psychiatric Research* 90 86-93.
- Laprevote, V., Bon, L., Krieg, J., Schwitzer, T., Bourion-Bedes, S., Maillard, L. et al. (2017). Association between increased EEG signal complexity and cannabis dependence. *European Neuropsychopharmacology* 27 (12) 1216-1222.
- Le Boisselier, R., Alexandre, J., Lelong-Boulouard, V. and Debruyne, D. (2017). Focus on cannabinoids and synthetic cannabinoids. *Clinical Pharmacology and Therapeutics* 101 (2) 220-229.
- Loose, T., Acier, D., Pilet, J.-L. and Sysaykeo, J. (2017). La temporalité. Un facteur déterminant des conduites addictives [Temporality: a determining factor in addictive behaviour]. *Alcoologie et Addictologie* 39 (2) 111-119.
- Marehin, M.S. (2017). Cannabis et psychose ordinaire. *Pratiques en santé mentale* 63 (2) 29-34.
- Marsot, A., Audebert, C., Attolini, L., Lacarelle, B., Micallef, J. and Blin, O. (2017). Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. *Journal of Pharmacological and Toxicological Methods* 85 49-54.

- Masson, M. (2017). Troubles bipolaires et addictions : la double peine. *Santé Mentale* (223) 20-25.
- Nicolas, C., Tauber, C., Lepelletier, F.X., Chalon, S., Belujon, P., Galineau, L. et al. (2017). Longitudinal changes in brain metabolic activity after withdrawal from escalation of cocaine self-administration. *Neuropsychopharmacology* 42 (10) 1981-1990.
- Patel, S., Leibrand, C.R., Palasuberniam, P., Couraud, P.O., Weksler, B., Jahr, F.M. et al. (2017). Effects of HIV-1 Tat and methamphetamine on blood-brain barrier integrity and function in vitro. *Antimicrobial Agents and Chemotherapy* 61 (12).
- Pedron, S., Beverley, J., Haffen, E., Andrieu, P., Steiner, H. and Van Waes, V. (2017). Transcranial direct current stimulation produces long-lasting attenuation of cocaine-induced behavioral responses and gene regulation in corticostratial circuits. *Addiction Biology* 22 (5) 1267-1278.
- Pelissier, F., Claudet, I., Gandia-Mailly, P., Benyamina, A. and Franchitto, N. (2016). Cannabis hyperemesis syndrome in the emergency department: How can a specialized addiction team be useful? A pilot study. *Journal of Emergency Medicine* 51 (5) 544-551.
- Ruppert, A.M., Perrin, J., Khalil, A., Vieira, T., Abou-Chedid, D., Masmoudi, H. et al. (2018). Effect of cannabis and tobacco on emphysema in patients with spontaneous pneumothorax. *Diagnostic and Interventional Imaging* 10.1016/j.diii.2018.01.017.
- Salaberry, N.L., Mateo, M. and Mendoza, J. (2017). The clock gene Rev-Erba regulates methamphetamine actions on circadian timekeeping in the mouse brain. *Molecular Neurobiology* 54 (7) 5327-5334.
- Salery, M., Dos Santos, M., Saint-Jour, E., Moumné, L., Pagès, C., Kappès, V. et al. (2017). Activity-regulated cytoskeleton-associated protein accumulates in the nucleus in response to cocaine and acts as a brake on chromatin remodeling and long-term behavioral alterations. *Biological Psychiatry* 81 (7) 573-584.
- Schreck, B., Wagneur, N., Caillet, P., Gérardin, M., Cholet, J., Spadari, M. et al. (2018). Cannabinoid hyperemesis syndrome: Review of the literature and of cases reported to the French addictovigilance network. *Drug and Alcohol Dependence* 182 27-32.
- Scocard, A., Benyamina, A., Coscas, S. and Karila, L. (2017). Cannabinoïdes de synthèse : une nouvelle matrice des addictions [Synthetic cannabinoids: A new addiction matrix]. *La Presse Médicale* 46 (1) 11-22.
- Sinnasse, P. and Tereno, S. (2017). Consommations d'alcool, de cannabis et de tabac et qualité d'attachement [Alcohol, cannabis and tobacco consumptions and attachment quality]. *Annales Médico-Psychologiques* 175 (4) 370-375.
- Tournebize, J., Gibaja, V. and Kahn, J.P. (2017). Acute effects of synthetic cannabinoids: Update 2015. *Substance Abuse* 38 (3) 344-366.
- Underner, M., Perriot, J. and Peiffer, G. (2017). Pneumomédiastin et consommation de cocaïne [Pneumomediastinum and cocaine use]. *La Presse Médicale* 46 (3) 249-262.
- Underner, M., Perriot, J., Peiffer, G. and Jaafari, N. (2017). Asthme et usage d'héroïne [Asthma and heroin use]. *La Presse Médicale* 46 (7-8 Part 1) 660-675.
- Wendland, J., Lebert, A., de Oliveira, C. and Boujut, E. (2017). Links between maltreatment during childhood or adolescence and risk-related substance use among young adults. *L'Evolution Psychiatrique* 82 (2) 383-393.
- Wolff, V. and Jouanjas, E. (2017). Strokes are possible complications of cannabinoids use. *Epilepsy and Behavior* 70, Part B 355-363.

**(2) Population based and clinical epidemiology  
(including site surveys, ethnographic studies and acute toxicity studies)**

- Baggio, S., Dupuis, M., Richard, J.-B. and Beck, F. (2017). Addictive behaviors and healthcare renunciation for economic reasons in a French population-based sample. *International Journal of Drug Policy* 49 1-7.
- Bailly, D. (2017). Les adolescents abstinents : un groupe à risque ? [The adolescent abstainers: A risk group?]. *L'Encéphale* 43 (5) 480-485.
- Barraud, H., Ehrhart, S. and Bronowicki, J.P. (2017). Toxicomanie et hépatite chronique C. *Hépato-Gastro et Oncologie Digestive* 24 (3) 233-239.
- Beck, F. (2017). Usages des drogues et pratiques addictives en France [Drug use and addictive practices in France]. *Soins* (816) 26-29.
- Beck, F. and Obradovic, I. (2017). Le cannabis en France. Totem ou tabou ? *Esprit* (2) 72-84.
- Beck, F., Obradovic, I., Adès, J.-E. and Lermenier-Jeannet, A. (2017). Regards sur les pratiques addictives des jeunes [Perspectives on youth addictive behaviours in France]. *Cahiers de la puéricultrice* 54 (307) 12-16.
- Beck, F., Obradovic, I., Palle, C., Brisacier, A.-C., Cadet-Taïrou, A., Díaz Gómez, C. et al. (2017). Usages de drogues et conséquences : quelles spécificités féminines ? *Tendances*. OFDT (117).
- Beck, F., Spilka, S., Nguyen-Thanh, V., Gautier, A., Le Nézet, O., Richard, J.-B. et al. (2017). Cannabis : usages actuels en population adulte. Résultats de l'enquête Baromètre santé 2016. *Tendances*. OFDT (119).
- Claudet, I., Le Breton, M., Bréhin, C. and Franchitto, N. (2017). A 10-year review of cannabis exposure in children under 3-years of age: do we need a more global approach? *European Journal of Pediatrics* 176 (4) 553-556.
- Claudet, I., Mouvier, S., Labadie, M., Manin, C., Michard-Lenoir, A.-P., Eyer, D. et al. (2017). Unintentional cannabis intoxication in toddlers. *Pediatrics* 140, (3), e20170017, 10.1542/peds.2017-0017.
- Devault, D.A., Levi, Y. and Karolak, S. (2017). Applying sewage epidemiology approach to estimate illicit drug consumption in a tropical context: Bias related to sewage temperature and pH. *Science of the Total Environment* 584-585 252-258.
- Dupouy, J., Palmaro, A., Fatséas, M., Auriaccombe, M., Micallef, J., Oustric, S. et al. (2017). Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: A 7-year cohort study. *Annals of Family Medicine* 15 (4) 355-358.
- Fernandes Pereira, P. and Simon, C. (2017). Consommations de substances psycho-actives en milieu carcéral : étude qualitative rétrospective [Substance psychoactive use in prison: a retrospective qualitative study]. *Psychotropes* 23 (2) 35-56.
- Frauger, E., Pochard, L., Boucherie, Q., Giocanti, A., Chevalier, C., Daveluy, A. et al. (2017). Dispositif pharmacoépidémiologique de surveillance des substances psychoactives : intérêts du programme national OPPIDUM du Réseau français d'addictovigilance [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network]. *Thérapie* 72 (4) 491-501.
- Guardia, D., Salleron, J., Roelandt, J.L. and Vaiva, G. (2017). Prévalence des troubles psychiatriques et addictologiques auprès de trois générations successives de migrants : résultats d'une étude menée en population générale [Prevalence of psychiatric and substance use disorders

among three generations of migrants: Results from French population cohort]. *L'Encéphale* 43 (5) 435-443.

Icick, R., Karsinti, E., Lépine, J.P., Bloch, V., Brousse, G., Bellivier, F. et al. (2017). Serious suicide attempts in outpatients with multiple substance use disorders. *Drug and Alcohol Dependence* 181 63-70.

Janssen, E. (2017). Estimating the number of people who inject drugs: a proposal to provide figures nationwide and its application to France. *Journal of Public Health* 10.1093/pubmed/fdx059.

Janssen, E., Spilka, S. and Beck, F. (2017). Suicide, santé mentale et usages de substances psychoactives chez les adolescents français en 2014 [Suicide, mental health and substance uses among French adolescents in 2014]. *Revue d'Epidémiologie et de Santé Publique* 65 (6) 409-417.

Jauffret-Roustide, M., Serebroshkaya, M.D., Chollet, A., Barin, F., Pillonel, J., Sommen, C. et al. (2017). Comparaison des profils, pratiques et situation vis-à-vis de l'hépatite C des usagers de drogues russophones et francophones à Paris. Enquête ANRS-Coquelicot, 2011-2013 [Comparison of social profiles, practices and situation toward hepatitis C among Russian-speaking and French-speaking drug users in Paris, France. ANRS-Coquelicot Study, 2011-2013]. *Bulletin épidémiologique hebdomadaire* (14-15) 285-290.

Jeanne, G., Purper-Ouakil, D., Rigole, H. and Franc, N. (2017). Nouveaux styles de consommation de produits psychoactifs chez les adolescents en France [New patterns of substance use and abuse among French adolescents, a knowledge synthesis]. *L'Encéphale* 43 (4) 346-353.

Jouanlus, E., Raymond, V., Lapeyre-Mestre, M. and Wolff, V. (2017). What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review. *Current Atherosclerosis Reports* 19 (6) 26.

Legleye, S. (2017). The Cannabis Abuse Screening Test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis. *International Journal of Methods in Psychiatric Research* 10.1002/mpr.1597.

Legleye, S. and Rouquette, A. (2018). Age invariance of the Cannabis Abuse Screening Test in a probabilistic sample of cannabis users. *European Addiction Research* 24 (1) 37-42.

Lermenier-Jeannet, A., Cadet-Taïrou, A. and Gautier, S. (2017). Profils et pratiques des usagers des CAARUD en 2015 [CAARUD client profiles and practices in 2015]. *Tendances*. OFDT (120).

Marcellin, F., Protopopescu, C., Esterle, L., Wittkop, L., Piroth, L., Aumaitre, H. et al. (2017). Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). *European Journal of Gastroenterology and Hepatology* 29 (7) 786-791.

Martin, J.-L., Gadegbeku, B., Wu, D., Viallon, V. and Laumon, B. (2017). Cannabis, alcohol and fatal road accidents. *PLoS One* 12 (11) e0187320.

Melchior, M., Bolze, C., Fombonne, E., Surkan, P.J., Pryor, L. and Jauffret-Roustide, M. (2017). Early cannabis initiation and educational attainment: is the association causal? Data from the French TEMPO study. *International Journal of Epidemiology* 46 (1) 1641-1650.

Nordmann, S., Vilotitch, A., Lions, C., Michel, L., Mora, M., Spire, B. et al. (2017) Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial). *PLoS One* 12 (5) e0176288.

Obradovic, I. (2017). Adolescence et substances psychoactives. *Soins* (816) 36-38.

- Obradovic, I. (2017). Représentations, motivations et trajectoires d'usage de drogues à l'adolescence [Perceptions, motives and trajectories associated with drug use in adolescents]. Tendances. OFDT (122).
- Obradovic, I. (2017). Tabac, alcool et drogues illicites à l'adolescence. Évolution des consommations et enjeux. Revue des politiques sociales et familiales (125) 73-79.
- Parriault, M.C., Van-Melle, A., Basurko, C., Valmy, L., Hoen, B., Cabie, A. et al. (2017). Sexual risk behaviors and predictors of inconsistent condom use among crack cocaine users in the French overseas territories in the Americas. International Journal of STD and AIDS 28 (13) 1266-1274.
- Peyrière, H., Diot, C., Nogue, E., Verschave, M., Laure, M., Picot, M.C. et al. (2017). Prevalence of antipsychotic-treated patients in a cohort of adult addicted patients. Journal of Clinical Psychopharmacology 37 (6) 669-674.
- Pochard, L., Dupouy, J., Frauger, E., Giocanti, A., Micallef, J. and Lapeyre-Mestre, M. (2018). Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France. Fundamental and Clinical Pharmacology 32 (2) 188-197.
- Prouvost-Keller, B., Naqvi, A., Joulié, A., Cua, E., Pradier, C. and Roger, P.M. (2017). Caractéristiques et facteurs de risque de consommation de produits psychoactifs au cours des relations sexuelles de patients fréquentant des lieux de dépistage ou de prise en charge du VIH et des hépatites virales dans le Sud-Est de la France en 2015 [Characteristics and risk factors associated to the consumptions of psychoactive products during sexual intercourse of patient attending HIV and viral hepatitis screening management centers in Southern France in 2015]. Bulletin épidémiologique hebdomadaire (21) 455-463.
- Sahajian, F., Berger-Vergiat, A. and Pot, E. (2017). Use of psychoactive substances in prison: Results of a study in the Lyon-Corbas prison, France. Revue d'Epidémiologie et de Santé Publique 65 (5) 361-367.
- Spilka, S. (2017). Usages de drogues des adolescents à Paris et en Seine-Saint-Denis. Une exploitation territoriale d'ESCAPAD 2014. Tendances. OFDT (116).
- Suzan-Monti, M., Cotte, L., Fressard, L., Cua, E., Capitant, C., Meyer, L. et al. (2018) Factors associated with partner notification of STIs in men who have sex with men on PrEP in France: a cross-sectional substudy of the ANRS-IPERGAY trial. Sexually Transmitted Infections 10.1136/sextrans-2017-053304, 10.1136/sextrans-2017-053304.
- (3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research)**
- Aknine, X., Carmona, D. and Carrois, F. (2018). Évaluation des séroconversions Hépatite C chez des patients traités par des médicaments de substitution aux opiacés suivis en ville par leur médecin généraliste [Evaluation of hepatitis C seroconversions in patients treated with opioid substitutes followed up in the community by their general practitioner]. Alcoologie et Addictologie 40 (1) 16-22.
- Barré, T., Vorspan, F., Fortias, M., Veyrier, M., Cavagna, P., Azuar, J. et al. (2018) Pratique de l'ATU de cohorte de la naloxone intranasale (Nalscue®): mise en place dans un CSAPA parisien [Temporary approval for intranasal naloxone: Setting up in a French addiction center]. Thérapie 10.1016/j.therap.2018.03.003, 10.1016/j.therap.2018.03.003.
- Beauvillier, E., Bonnet, N. and Cornibert, A.-C. (2017). Évaluation multicentrique de programmes d'échange de seringues en pharmacie [Multi-centre evaluation of syringe exchange programmes in pharmacy]. Psychotropes 23 (2) 73-85.

- Benoit, E. (2017). Prévenir la consommation de cannabis chez les jeunes, réalité ou utopie ? *Pratiques en santé mentale* 63 (2) 35-38.
- Benso, V. (2017). Technoplus et la réduction des risques en espace festif. Apports de l'auto support. *Chimères* 10.3917/chime.091.0055 (91) 55-62.
- Biseul, I., Icick, R., Seguin, P., Bellivier, F. and Scott, J. (2017). Feasibility and acceptability of the 'HABIT' group programme for comorbid bipolar and alcohol and substance use disorders. *Clinical Psychology and Psychotherapy* 24 (4) 887-898.
- Chavignaud, I. and Lafaye, G. (2017). Accompagnement des conduites addictives du personnel soignant [Support for addictive behaviour among nursing staff]. *Soins* (816) 45-47.
- Clergue-Duval, V., Robin, S., Fortias, M., Dupuy, G., Badin-de-Montjoye, B. and Vorspan, F. (2017). Use and knowledge of contraceptive methods by patients in two substance use disorders treatment centers in Paris. *Harm Reduction Journal* 14 (54).
- Dano, C. (2017). Prévenir les pratiques addictives en milieu professionnel grâce aux services de santé au travail [Preventing addictive practices in the workplace thanks to occupational health services]. *Soins* (816) 39-42.
- Estingoy, P. (2018). L'abstinence cannabique : un enjeu pour la réhabilitation. *Annales Médico-psychologiques, revue psychiatrique* 176 (1) 84-88.
- Gaissad, L. (2017). Réduire quels risques ? Chemsex et avatars du plaisir et de la santé gay. *Chimères* 10.3917/chime.091.0169 (91) 169-177.
- Jauffret-Roustide, M. (2017). Acceptabilité et techniques d'appropriation par les usagers des outils de réduction des risques liés à l'injection - évaluation du Steribox® [Acceptability and techniques of appropriation employed by users of tools aimed at the reduction of the risks linked to injection - evaluation of the Steribox®]. *Psychotropes* 23 (2) 87-109.
- Jauffret-Roustide, M., Chollet, A., Santos, A., Benoit, T., Péchiné, S., Duplessy, C. et al. (2018). Theory versus practice, bacteriological efficiency versus personal habits: A bacteriological and user acceptability evaluation of filtering tools for people who inject drugs. *Drug and Alcohol Review* 37 (1) 106-115.
- Kempf, C., Llorca, P.M., Pizon, F., Brousse, G. and Flaudias, V. (2017). What's new in addiction prevention in young people: A literature review of the last years of research. *Frontiers in Psychology* 8 (1131).
- Lorraine, S. (2017). Les addictions en milieu scolaire, rôle de l'infirmière [Addictions in schools, the role of the nurse]. *Soins* (816) 43-44.
- Lucet, C., Dupouy, J., Rousselet, A.V., Caron, M., Polin, R. and Laqueille, X. (2017). Une aide à la prise en charge du craving sur smartphone [Assistance for the treatment of cravings on smartphones]. *Soins Psychiatrie* 38 (311) 37-39.
- Marie-Claire, C., Jourdaine, C., Lepine, J.P., Bellivier, F., Bloch, V. and Vorspan, F. (2017). Pharmacogenomics of opiates and methadone maintenance treatment: current data and perspectives. *Pharmacogenomics* 18 (14) 1359-1372.
- Milhet, M. and Jauffret-Roustide, M. (2017). Réduire les risques liés à l'injection de drogues au moyen d'un nouvel outil de filtration : le point de vue des usagers de drogues [The role of a new syringe filter in harm reduction: the views of active injection drug users]. *Santé Publique* 29 (3) 311-320.
- Monod, G. (2017). Cannabis et prison. *Pratiques en santé mentale* 63 (2) 39-42.

- Panhaleux, N. and Mantelet, C. (2017). L'infirmière en centre de soins, d'accompagnement et de prévention en addictologie [The nurse in an addiction treatment, support and prevention centre]. *Soins* (816) 50-52.
- Pitrat, B. (2017). Quels usages pour les outils numériques en addictologie et médecine du sommeil ? [Where can new technologies be most effective in the patient-psychiatrist relationship as regards addiction and sleep medicine?]. *L'Information Psychiatrique* 93 (8) 649-653.
- Poirier, F. and Biard, N. (2017). Prévention et prise en compte des pratiques addictives aux urgences [Prevention and understanding of addictive practices in emergency departments]. *Soins* (816) 48-49.
- Reyre, A., Jeannin, R., Largueche, M., Moro, M.R., Baubet, T. and Taieb, O. (2017). Overcoming professionals' challenging experiences to promote a trustful therapeutic alliance in addiction treatment: A qualitative study. *Drug and Alcohol Dependence* 174 30-38.
- Richaud, E. (2017). Qu'est-ce qu'être psychologue en CAARUD ? Éléments de réflexions théoriques à partir d'une expérience professionnelle au CAARUD de Saint-Denis [What is a psychologist at a CAARUD?]. *Psychotropes* 23 (2) 9-33.
- Rigaud, L., de Bazelaire, S. and Romo, L. (2017). Utilisation d'outils numériques en vue du traitement de l'addiction au cannabis d'un public francophone : synthèse de la recherche [Use of electronic tools to treat cannabis addition in a francophone population: a research overview]. *Alcoologie et Addictologie* 39 (1) 23-33.
- Roux, P., Debrus, M., Rojas Castro, D., Bladou, F., Suzan-Monti, M., Avril, E. et al. (2017). De la recherche communautaire à la transformation sociale : l'exemple du projet ANRS-AERLI sur l'accompagnement et l'éducation aux risques liés à l'injection [From community-based research to social transformation: the example of the ANRS-AERLI project on injecting risk education and support]. *Psychotropes* 23 (2) 57-72.
- Roux, P., Rojas Castro, D., Ndiaye, K., Briand Madrid, L., Laporte, V., Mora, M. et al. (2017). Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. *Substance Abuse Treatment, Prevention, and Policy* 12 (46).
- Sabbah-Lim, I. and Yakoub, S. (2018). Prise en charge des parents dans les addictions comportementales de l'adolescent [Caring systems for parents in the adolescent behavioural addictions]. *La Revue du Praticien - Monographie* 68 (3) 319-322.
- Tapia, G., Perez-Dandieu, B., Lenoir, H., Othily, E., Gray, M. and Delile, J.-M. (2018). Treating addiction with schema therapy and EMDR in women with co-occurring SUD and PTSD: A pilot study. *Journal of Substance Use* 23 (2) 199-205.
- Wagner, V. and Acier, D. (2017). Étude des départs prématurés de patients admis en addictologie [Premature discharge of addictology patients: a study]. *Alcoologie et Addictologie* 39 (4) 340-349.

#### **(4) Supply, supply reduction and crime**

- Cadet-Taïrou, A., Gandilhon, M., Martinez, M., Milhet, M. and Néfau, T. (2017). Substances psychoactives, usagers et marchés : les tendances récentes (2016-2017) [Psychoactive substances, users and markets: recent trends (2016-2017)]. *Tendances*. OFDT (121).

### **(5) Drug policy (including laws, economic issues and strategies)**

Coppel, A. (2017). Des usagers de drogues aux experts de l'ONU, les trois bascules de la politique des drogues. Chimères 10.3917/chime.091.0030 (91) 30-42.

Kopp, P. and Ogorodnik, M. (2017). The social cost of drugs in France in 2010. European Journal of Health Economics 18 (7) 883-892.

Le Boeuf, D. (2017). La lutte contre les conduites addictives en France [The fight against addictive behaviour in France]. Soins (816) 30-32.

### **(6) Other topics**

Arveiller, J. (2017). Cannabis et formation du médecin. Moreau de Tours et ses internes. Pratiques en santé mentale 63 (2) 21-28.

Curtef, F. (2017). Cannabis et enjeux sociétaux. Pratiques en santé mentale 63 (2) 5-8.

Nourrisson, D. (2017). La représentation des drogues dans l'histoire des sociétés. Le cas français [Representation of drugs in the societal history. The French case]. Drogues, santé et société 16 (2) 1-14.

Vuillaume, D. (2017). Renouveler les débats actuels sur les drogues et les dépendances. Implications Philosophiques (22 décembre 2017).

## **T4. Additional information**

The purpose of this section is to provide additional information important to drug-related research in your country that has not been provided elsewhere.

**T4.1 Optional.** Please describe any additional important sources of information, specific studies or data on drug-related research. Where possible, please provide references and/or links.

**T4.2 Optional.** Please describe any other important aspect of drug-related research that has not been covered in the specific questions above. This may be additional information, a reference to an organisation in your country that monitors national drug-related research, the availability of a bibliography of recent studies or new areas of specific importance for your country.

## **T5. Notes and queries**

The purpose of this section is to highlight areas of specific interest for possible future elaboration. Detailed answers are not required.

Yes/No answers required. If yes please provide brief additional information.  
No current questions.

## T6. Sources and methodology

The purpose of this section is to collect sources for the information provided above, including brief descriptions of studies and their methodology where appropriate.

T6.1 Please list notable sources for the information provided above.

Please note that this workbook was pre-filled in using the information provided through the bibliography of your national report. If you used other sources while reviewing/correcting it, please list them here.

T.6.2 Where studies or surveys have been used please list them and where appropriate describe the methodology